KR102310704B1 - 장기 작용 응고 인자들 및 이를 생산하는 방법들 - Google Patents

장기 작용 응고 인자들 및 이를 생산하는 방법들 Download PDF

Info

Publication number
KR102310704B1
KR102310704B1 KR1020207015367A KR20207015367A KR102310704B1 KR 102310704 B1 KR102310704 B1 KR 102310704B1 KR 1020207015367 A KR1020207015367 A KR 1020207015367A KR 20207015367 A KR20207015367 A KR 20207015367A KR 102310704 B1 KR102310704 B1 KR 102310704B1
Authority
KR
South Korea
Prior art keywords
ctp
another embodiment
coagulation factor
polypeptide
fix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015367A
Other languages
English (en)
Korean (ko)
Other versions
KR20200063274A (ko
Inventor
우디 이얄 피마
길리 하트
Original Assignee
옵코 바이오로직스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102310704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by 옵코 바이오로직스 리미티드 filed Critical 옵코 바이오로직스 리미티드
Priority to KR1020217031683A priority Critical patent/KR102630953B1/ko
Publication of KR20200063274A publication Critical patent/KR20200063274A/ko
Application granted granted Critical
Publication of KR102310704B1 publication Critical patent/KR102310704B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
KR1020207015367A 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들 Active KR102310704B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217031683A KR102630953B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/372,540 2012-02-14
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same
KR1020147025500A KR102118729B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들
PCT/IL2013/050107 WO2013121416A1 (en) 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025500A Division KR102118729B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031683A Division KR102630953B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들

Publications (2)

Publication Number Publication Date
KR20200063274A KR20200063274A (ko) 2020-06-04
KR102310704B1 true KR102310704B1 (ko) 2021-10-08

Family

ID=48983616

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147025500A Active KR102118729B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들
KR1020217031683A Active KR102630953B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들
KR1020207015367A Active KR102310704B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020147025500A Active KR102118729B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들
KR1020217031683A Active KR102630953B1 (ko) 2012-02-14 2013-02-05 장기 작용 응고 인자들 및 이를 생산하는 방법들

Country Status (22)

Country Link
EP (4) EP3326642B1 (enExample)
JP (2) JP6242819B2 (enExample)
KR (3) KR102118729B1 (enExample)
CN (2) CN109535245A (enExample)
AU (3) AU2013219935B2 (enExample)
BR (1) BR122021004014B1 (enExample)
CA (1) CA2870621C (enExample)
CL (2) CL2014002183A1 (enExample)
CO (1) CO7131365A2 (enExample)
DK (2) DK2822576T3 (enExample)
EA (2) EA028578B1 (enExample)
ES (3) ES2665319T3 (enExample)
HU (1) HUE053068T2 (enExample)
IL (2) IL264959B (enExample)
MX (3) MX362446B (enExample)
MY (1) MY172539A (enExample)
NO (1) NO2920022T3 (enExample)
PE (1) PE20142290A1 (enExample)
PL (2) PL3326642T3 (enExample)
PT (1) PT3791890T (enExample)
SG (1) SG11201404836QA (enExample)
WO (1) WO2013121416A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN109535245A (zh) 2012-02-14 2019-03-29 奥普科生物制品有限公司 长效凝血因子和生产它们的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
SG11201704706RA (en) * 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
WO2018011799A1 (en) * 2016-07-11 2018-01-18 Opko Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (en) * 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004361A2 (en) * 2009-07-09 2011-01-13 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
KR102118729B1 (ko) * 2012-02-14 2020-06-05 옵코 바이오로직스 리미티드 장기 작용 응고 인자들 및 이를 생산하는 방법들

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
BR112015011583B1 (pt) * 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004361A2 (en) * 2009-07-09 2011-01-13 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
KR102118729B1 (ko) * 2012-02-14 2020-06-05 옵코 바이오로직스 리미티드 장기 작용 응고 인자들 및 이를 생산하는 방법들

Also Published As

Publication number Publication date
KR102118729B1 (ko) 2020-06-05
EA201790960A3 (ru) 2018-01-31
KR20210125595A (ko) 2021-10-18
CN104427994A (zh) 2015-03-18
MY172539A (en) 2019-11-30
WO2013121416A1 (en) 2013-08-22
EP2822576B1 (en) 2018-01-10
EP4488289A3 (en) 2025-03-19
JP2018065815A (ja) 2018-04-26
CL2014002183A1 (es) 2015-01-09
AU2017219044B2 (en) 2019-05-30
IL282121A (en) 2021-05-31
ES3010346T3 (en) 2025-04-02
HK1205460A1 (en) 2015-12-18
JP2015508771A (ja) 2015-03-23
DK3326642T3 (da) 2021-02-22
MX2019000708A (es) 2020-09-02
EP3791890A1 (en) 2021-03-17
IL264959B (en) 2021-08-31
EP2822576A1 (en) 2015-01-14
MX393997B (es) 2025-03-24
PT3791890T (pt) 2025-02-14
ES2665319T3 (es) 2018-04-25
EP3326642A1 (en) 2018-05-30
EP3791890B1 (en) 2024-11-13
AU2016202829A1 (en) 2016-05-19
MX2014009910A (es) 2015-09-28
BR122021004014B1 (pt) 2022-12-27
CA2870621C (en) 2022-08-09
AU2017219044A1 (en) 2017-09-14
CN109535245A (zh) 2019-03-29
CL2017002233A1 (es) 2018-05-11
BR112014020198A2 (pt) 2018-05-15
AU2013219935A1 (en) 2014-09-25
KR20200063274A (ko) 2020-06-04
DK2822576T3 (en) 2018-04-16
JP6510002B2 (ja) 2019-05-08
CO7131365A2 (es) 2014-12-01
IL282121B (en) 2022-06-01
EP2822576A4 (en) 2015-11-25
EA028578B1 (ru) 2017-12-29
SG11201404836QA (en) 2014-12-30
MX2022008807A (es) 2022-08-11
EA201491519A1 (ru) 2014-12-30
ES2855133T3 (es) 2021-09-23
JP6242819B2 (ja) 2017-12-06
MX362446B (es) 2019-01-18
KR20140134673A (ko) 2014-11-24
EP3326642B1 (en) 2020-11-25
PE20142290A1 (es) 2015-01-15
AU2016202829B2 (en) 2017-05-25
PL3791890T3 (pl) 2025-04-14
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
EP4488289A2 (en) 2025-01-08
HUE053068T2 (hu) 2021-06-28
EA201790960A2 (ru) 2017-09-29
NO2920022T3 (enExample) 2018-06-09
CA2870621A1 (en) 2013-08-22
AU2013219935B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
KR102310704B1 (ko) 장기 작용 응고 인자들 및 이를 생산하는 방법들
JP6430592B2 (ja) 長期作用性凝固因子およびそれを製造する方法
US10144921B2 (en) Long-acting coagulation factors and methods of producing same
US8759292B2 (en) Long-acting coagulation factors and methods of producing same
US11066658B2 (en) Long-acting coagulation factors and methods of producing same
KR102473014B1 (ko) 장기-작용성 응고 인자 및 그의 제조 방법
US12203113B2 (en) Long-acting coagulation factors and methods of producing same
HK40120325A (en) Long-acting coagulation factors and uses thereof
EA044349B1 (ru) Факторы свертывания крови пролонгированного действия и способы их получения

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5